Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone in Pulmonary Arterial Hypertension
NCT01712620Phase 2Recruiting
- Sponsor
- National Institutes of Health
- Start
- Jan 2014
- Primary completion
- Dec 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of spironolactone in pulmonary arterial hypertension (PAH), sponsored by National Institutes of Health. Started Jan 2014; status: recruiting.
02
Drugs
spironolactone
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01712620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01712620.